Meloxicam

The exact dog-only 1.5 mg/ml suspension has a valid Spanish authorisation in the EU Union Product Database, current official product information, and active Georgian veterinary registrations for 10, 25 and 125 ml packs. It is an Article 13(1) generic with a clearly identified marketing-authorisation holder and manufacturing site; the older GB authorisation has expired and is not counted as current.

Randomized placebo-controlled and comparator trials support clinically meaningful improvement in canine osteoarthritis and chronic musculoskeletal pain with oral meloxicam, including the labelled 0.2 mg/kg loading and 0.1 mg/kg once-daily maintenance regimen. Evidence is mature and consistent, while individual response still requires objective reassessment and multimodal management.

Canine meloxicam safety is well characterised, but gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious or rarely fatal. Risk rises with dehydration, hypovolaemia, hypotension, organ disease, overdose, prolonged exposure or overlap with another NSAID, corticosteroid or nephrotoxic treatment.

Once-daily dosing, a ready 1.5 mg/ml suspension, food administration and the supplied kg-calibrated syringe make home delivery and weight-based measurement straightforward. The bottle must be shaken, day-one volume doubled correctly, response checked within 3-4 days, and longer treatment coupled to risk-based clinical and laboratory monitoring.

The exact 100 ml vial is registered in Georgia (000630, valid to 2029) with a current Turkish manufacturer label whose dog and cat doses mirror the EU reference (Metacam), but it has no EU, UK or US authorisation documented in the reviewed evidence and no public bioequivalence data.

Meloxicam 0.2 mg/kg is a well-proven perioperative and musculoskeletal analgesic in dogs and is supported by pain guidelines; the formulation's equivalence to the reference is assumed, not shown.

NSAID risks are real: the label excludes dogs under 6 weeks, pregnant or lactating, dehydrated or hypotensive dogs, and liver, heart, kidney, bleeding or gastrointestinal disease, and bans combination with glucocorticoids, other NSAIDs or anticoagulants.

At 0.04 ml/kg a single injection is easy to draw up, but a 100 ml multi-species vial is far more than a small-animal clinic usually uses, so expect long storage or discard after broaching.

The exact 100 ml vial is registered in Georgia (000630, valid to 2029) with a current Turkish manufacturer label whose dog and cat doses mirror the EU reference (Metacam), but it has no EU, UK or US authorisation documented in the reviewed evidence and no public bioequivalence data.

A single 0.3 mg/kg meloxicam dose before surgery is a proven postoperative analgesic in cats; equivalence of this formulation to the reference is assumed, not shown.

Cats are sensitive to NSAIDs and kidney risk rises with dehydration or hypotension under anaesthesia; at 5 mg/ml the dose is only 0.06 ml/kg, so a small measuring error becomes a large overdose.

A 4 kg cat needs 0.24 ml, which requires an insulin or 1 ml syringe, and the 100 ml cattle-sized vial is poorly suited to feline practice.

The exact Bioveta formulation is registered in Georgia and has current official EU product information; meloxicam also has mature international regulatory review and long clinical use.

Randomized and comparative studies support clinically meaningful analgesic and anti-inflammatory efficacy in canine osteoarthritis and musculoskeletal pain, with extensive class-level experience.

The safety profile is well characterised but not benign: gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious, especially with dehydration, comorbidity, overdose or NSAID/corticosteroid overlap.

Injection is useful when oral dosing is unsuitable and allows controlled peri-operative use, but requires veterinary administration and careful timing around anaesthesia and fluid status.

The exact 5 mg/ml Bioveta injection is registered in Georgia with current official EU product information, and injectable meloxicam has mature international regulatory review in cats.

Randomized peri-operative trials support single-dose analgesic activity, but efficacy varies by procedure and comparator and meloxicam should remain one component of multimodal analgesia rather than sole rescue coverage.

Cats have a narrow NSAID safety margin; renal injury and gastrointestinal toxicity are major concerns with hypovolaemia, hypotension, renal disease, overdose or repeat dosing. The assessed role is strictly the labelled single injection.

A single veterinary injection is straightforward within an anaesthetic protocol, but timing, hydration and the absolute prohibition on unplanned repeat dosing require disciplined workflow.

The exact Bioveta formulation is registered in Georgia and has current official EU product information; meloxicam also has mature international regulatory review and long clinical use.

Randomized and comparative studies support clinically meaningful analgesic and anti-inflammatory efficacy in canine osteoarthritis and musculoskeletal pain, with extensive class-level experience.

The safety profile is well characterised but not benign: gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious, especially with dehydration, comorbidity, overdose or NSAID/corticosteroid overlap.

Once-daily oral suspension supports precise weight-based dosing and course adjustment, but the bottle must be shaken, the syringe used accurately and daily clinical monitoring maintained.